ClinicalTrials.gg
CompletedNCT00009737Updated Jun 22, 2016Results posted

A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer

A Phase 3 interventional study of 5-Fluorouracil and Leucovorin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 133 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-06-22.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,987
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 179 studies testing capecitabine in Colorectal Neoplasms — 24 open to participants now, 32 under way, 7 of them phase 3. Capecitabine · Colorectal Neoplasms.

Enrollment
7th of 173
1,987 · median 55
Started
1998
the only one that year
Phase 3
32 of 179
4 open now
Registered
2nd of 179
by date
Lead sponsor
16 of 179
Hoffmann-La Roche

Among the 179 studies testing capecitabine in Colorectal Neoplasms, this one is the 7th largest by enrollment of the 173 interventional ones that give a count, is the only one that started in 1998, is one of 32 in phase 3, and was the 2nd registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

24 of the 179 studies testing capecitabine in Colorectal Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 24 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies testing capecitabine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This 2 arm study will compare the safety and efficacy of oral Xeloda, or 5-fluorouracil in combination with leucovorin, in patients who have undergone surgery for colon cancer. Patients will be randomized to receive either Xeloda 1250mg/m2 po bid on days 1-14 every 21 days, or leucovorin 20mg/m2 iv + 5-fluorouracil 425mg/m2 iv daily from day 1 to day 5 every 28 days. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients 18-75 years of age;
  • confirmed colon cancer with potentially curative resection of the tumor within 8 weeks before study initiation.

Exclusion criteria

Exclusion Criteria:

  • previous chemotherapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,987 participants (actual)

Study arms

  • Experimental
    Capecitabine

    Participants received capecitabine 1250 milligram per square meter (mg/m \^ 2) orally, twice a day, for 14 days, followed by a 7-day rest period without treatment, as an intermittent therapy in a 3-week cycle for 8 cycles (24 weeks).

    Drug: Capecitabine [Xeloda]

  • Active comparator
    5-Fluorouracil + Leucovorin

    Participants received leucovorin 20 mg/m \^ 2 followed by 5-fluorouracil at 425 mg/m \^ 2, by rapid intravenous injection, daily, from Days 1 to 5 of the first week in each 4-week cycle for 6 cycles (24 weeks).

    Drug: 5-Fluorouracil · Drug: Leucovorin

Interventions

06

What researchers measure

Primary outcomes

  1. Disease-free Survival

    Participants with disease-free survival were reported. Disease-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participant was known to be disease free (censoring time).

    Time frame: Approximately 3 years

Secondary outcomes

  1. Relapse-Free Survival

    Participants with relapse-free survival were reported. Relapse-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participants was known to be disease free (censoring time), excluding deaths that were not related to treatment or to disease progression.

    Time frame: Approximately 3 years

  2. Overall Survival

    Participants with overall survival were reported. Overall survival was assessed as the number of days between randomization and death or the last time at which a participant was known to be alive (censoring time).

    Time frame: Approximately 3 years

  3. Mean Change From Baseline in Global Health Status at Week 25

    Global health status was assessed as a sub scale of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. It was scored on a scale of 0-100; where higher score indicates better quality of life. Wherever the scores for the participants were not available, the last value carried forward (LVCF) were used.

    Time frame: Baseline (Days -7 to 1) and at Week 25

  4. Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters

    Laboratory abnormalities were categorized according to the National Cancer Institute of Canada Common Toxicity Criteria (NCIC - CTC) grading system (May 1991 revised) as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (life- threatening). Participants with abnormalities in hemoglobin, granulocytes, lymphocytes, neutrophils, neutrophils/granulocytes, platelets, white blood cell, potassium, serum creatinine, sodium, total bilirubin, alanine transaminase, aspartate aminotransferase, alkaline phosphatase, calcium (hyper), and calcium (hypo) with Grades 1-4 were presented.

    Time frame: Up to Week 25

  5. Number of Participants With Any Adverse Events and Serious Adverse Events

    An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An Serious Adverse Events (SAEs) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.

    Time frame: Up to Week 29

07

Results

Posted Jun 22, 2016

Participant flow

A total of 1987 participants were recruited into the study across 164 centers in 25 countries. This study was conducted from 12 Nov 1998 to 01 Apr 2004.

Participant flow — Overall Study
MilestoneCapecitabine5-Fluorouracil + Leucovorin
Started1004983
Completed834860
Not completed170123
Withdrew: Adverse event11275
Withdrew: Death46
Withdrew: Lack of efficacy1715
Withdrew: Violation of selection criteria at entry139
Withdrew: Other protocol violation10
Withdrew: Refused treatment1516
Withdrew: Lost to follow-up11
Withdrew: Administrative/other reasons71

Outcome measures

PrimaryDisease-free Survival

Participants with disease-free survival were reported. Disease-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participant was known to be disease free (censoring time).

Time frame:
Approximately 3 years
Reported as:
Number · Participants
Disease-free Survival
ParticipantsCapecitabine5-Fluorouracil + Leucovorin
Disease-free Survival656603
Statistical analysis
  • Capecitabine vs 5-Fluorouracil + Leucovorin · Wald Chi-Square Test · p = 0.053 (For difference between arms, \< 0.001 for non-inferiority) · Hazard ratio (hr): 0.87 · 95% CI 0.75 to 1.00
SecondaryRelapse-Free Survival

Participants with relapse-free survival were reported. Relapse-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participants was known to be disease free (censoring time), excluding deaths that were not related to treatment or to disease progression.

Time frame:
Approximately 3 years
Reported as:
Number · Participants
Relapse-Free Survival
ParticipantsCapecitabine5-Fluorouracil + Leucovorin
Relapse-Free Survival677621
Statistical analysis
  • Capecitabine vs 5-Fluorouracil + Leucovorin · Wald Chi-Square Test · p = 0.041 (For difference between arms, \< 0.001 for non-inferiority) · Hazard ratio (hr): 0.86 · 95% CI 0.74 to 0.99
SecondaryOverall Survival

Participants with overall survival were reported. Overall survival was assessed as the number of days between randomization and death or the last time at which a participant was known to be alive (censoring time).

Time frame:
Approximately 3 years
Reported as:
Number · Participants
Overall Survival
ParticipantsCapecitabine5-Fluorouracil + Leucovorin
Overall Survival804756
Statistical analysis
  • Capecitabine vs 5-Fluorouracil + Leucovorin · Wald Chi-Square Test · p = 0.071 (For difference between arms, \< 0.001 for non-inferiority) · Hazard ratio (hr): 0.84 · 95% CI 0.69 to 1.01
SecondaryMean Change From Baseline in Global Health Status at Week 25

Global health status was assessed as a sub scale of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. It was scored on a scale of 0-100; where higher score indicates better quality of life. Wherever the scores for the participants were not available, the last value carried forward (LVCF) were used.

Time frame:
Baseline (Days -7 to 1) and at Week 25
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Global Health Status at Week 25
Score on a scaleCapecitabine5-Fluorouracil + Leucovorin
Mean Change From Baseline in Global Health Status at Week 252.1 ± 0.802.6 ± 0.78
SecondaryNumber of Participants With Abnormalities for Blood Chemistry and Hematological Parameters

Laboratory abnormalities were categorized according to the National Cancer Institute of Canada Common Toxicity Criteria (NCIC - CTC) grading system (May 1991 revised) as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (life- threatening). Participants with abnormalities in hemoglobin, granulocytes, lymphocytes, neutrophils, neutrophils/granulocytes, platelets, white blood cell, potassium, serum creatinine, sodium, total bilirubin, alanine transaminase, aspartate aminotransferase, alkaline phosphatase, calcium (hyper), and calcium (hypo) with Grades 1-4 were presented.

Time frame:
Up to Week 25
Reported as:
Number · Participants
Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters
ParticipantsCapecitabine5-Fluorouracil + Leucovorin
Alanine transaminase327333
Aspartate aminotransferase300288
Alkaline Phosphatase334289
Calcium (Hyper)6768
Calcium (Hypo)150112
Granulocytes2043
Hemoglobin691650
Lymphocytes778744
Neutrophils308596
Neutrophils/Granulocytes316612
Platelets182160
Potassium209156
Serum Creatinine157138
Sodium189184
Total Bilirubin501185
White blood cell220409
SecondaryNumber of Participants With Any Adverse Events and Serious Adverse Events

An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An Serious Adverse Events (SAEs) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.

Time frame:
Up to Week 29
Reported as:
Number · Participants
Number of Participants With Any Adverse Events and Serious Adverse Events
ParticipantsCapecitabine5-Fluorouracil + Leucovorin
All adverse events910885
Serious adverse events181182

Adverse events

Collected over Up to Week 29. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine—181/995 (18.2%)838/995 (84.2%)
5-Fluorouracil + Leucovorin—182/974 (18.7%)847/974 (87%)
Most frequent serious events
Showing 10 of 183
Most frequent serious events
EventCapecitabine5-Fluorouracil + Leucovorin
DiarrhoeaGastrointestinal disorders58/99534/974
*Stomatitis allGastrointestinal disorders4/99525/974
Febrile neutropeniaBlood and lymphatic system disorders3/99517/974
Abdominal painGastrointestinal disorders9/99510/974
Small intestinal obstructionGastrointestinal disorders7/99510/974
Deep vein thrombosisVascular disorders10/9956/974
Intestinal obstructionGastrointestinal disorders9/9953/974
DehydrationMetabolism and nutrition disorders8/9957/974
VomitingGastrointestinal disorders5/9957/974
NeutropeniaBlood and lymphatic system disorders3/9957/974
Most frequent other events
Showing 10 of 21
Most frequent other events
EventCapecitabine5-Fluorouracil + Leucovorin
DiarrhoeaGastrointestinal disorders437/995610/974
Palmar-plantarSkin and subcutaneous tissue disorders593/99585/974
Stomatitis allGastrointestinal disorders218/995574/974
NauseaGastrointestinal disorders334/995459/974
Erythrodysaesthesia syndrome AlopeciaSkin and subcutaneous tissue disorders63/995218/974
VomitingGastrointestinal disorders147/995199/974
FatigueGeneral disorders155/995150/974
Abdominal painGastrointestinal disorders133/995149/974
AnorexiaMetabolism and nutrition disorders90/995104/974
ConstipationGastrointestinal disorders86/995103/974

Baseline characteristics

All randomized population included all participants who were randomized to one of the two treatment arms, regardless of whether they received any study medication.

Age, Continuous
Age, Continuous(Years)Capecitabine5-Fluorouracil + LeucovorinTotal
Median62.0 (25 to 80)63.0 (22 to 82)62.0 (22 to 82)
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Capecitabine5-Fluorouracil + LeucovorinTotal
Female461451912
Male5425321074
Missing101
08

Study locations

133 sites
  • Birmingham, Alabama 35294, United States
  • Phoenix, Arizona 85012, United States
  • Fountain Valley, California 92708, United States
  • Los Angeles, California 90089, United States
  • Hartford, Connecticut 06102-5037, United States
  • Miami, Florida 33176, United States
  • Decatur, Georgia 30033, United States
  • Columbia, Missouri 65203, United States
  • St Louis, Missouri 63141, United States
  • Albany, New York 12208, United States
  • Buffalo, New York 14263, United States
  • Cleveland, Ohio 44195, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Nashville, Tennessee 37203-1632, United States
  • Austin, Texas 78705, United States
  • Tyler, Texas 75701, United States
  • Seattle, Washington 98195, United States
  • Buenos Aires, 1417, Argentina
  • Buenos Aires, 1425, Argentina
  • Buenos Aires, C1264AAA, Argentina
  • Buenos Aires, C1270AAE, Argentina
  • Adelaide, 5011, Australia
  • Bendigo, 3550, Australia
  • Brisbane, 4006, Australia
  • Fitzroy, 3065, Australia
  • Kurralta Park, 5037, Australia
  • Melbourne, 3128, Australia
  • Melbourne, 3181, Australia
  • Perth, 6000, Australia
  • Port Macquarie, 2444, Australia
  • St. Leonards, 2065, Australia
  • Sydney, 2217, Australia
  • Wodonga, 3690, Australia
  • Hall in Tirol, 6060, Austria
  • Innsbruck, 6020, Austria
  • Klagenfurt, 9026, Austria
  • Linz, 4010, Austria
  • Oberwart, 7400, Austria
  • St Pölten, 3100, Austria
  • Wien, 1030, Austria
  • Wien, 1090, Austria
  • Wien, 1100, Austria
  • Wien, 1160, Austria
  • Wien, 1220, Austria
  • Bruxelles, 1090, Belgium
  • Porto Alegre, 90020-090, Brazil
  • Rio de Janeiro, 20220-410, Brazil
  • Sao Paulo, 01406100, Brazil
  • Sorocaba, 18035-300, Brazil
  • Calgary, Alberta T2N 4N2, Canada
  • Kelowna, British Columbia V1Y 5L3, Canada
  • Winnipeg, Manitoba R2H 2A6, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • Montreal, Quebec H3G 1A4, Canada
  • Saskatoon, Saskatchewan S7N 4H4, Canada
  • Berlin, 13353, Germany
  • Braunschweig, 38100, Germany
  • Freiburg, 79106, Germany
  • Grenzach-wyhlen, 79639, Germany
  • Göttingen, 37073, Germany
  • Halle, 06108, Germany
  • Hannover, 30171, Germany
  • Kassel, 34125, Germany
  • Lehrte, 31275, Germany
  • Magdeburg, 39130, Germany
  • München, 81245, Germany
  • Oldenburg, 26121, Germany
  • Oldenburg, 26133, Germany
  • Ravensburg, 88212, Germany
  • Regensburg, 93053, Germany
  • Villingen-schwenningen, 78052, Germany
  • Wuppertal, 42210, Germany
  • Haifa, 34354, Israel
  • Petach Tikva, 49100, Israel
  • Petach Tikva, Israel
  • Rehovot, 76100, Israel
  • Tel Aviv, 6423906, Israel
  • Aviano, 33081, Italy
  • Bergamo, 24128, Italy
  • Bologna, 40138, Italy
  • Cuneo, 12100, Italy
  • Genova, 16132, Italy
  • Livorno, 57100, Italy
  • Mantova, 46100, Italy
  • Milano, 20121, Italy
  • Mirano, 30035, Italy
  • Modena, 41100, Italy
  • Napoli, 80131, Italy
  • Pisa, 56100, Italy
  • Roma, 00135, Italy
  • Roma, 00168, Italy
  • Roma, Italy
  • Terni, 05100, Italy
  • Torino, 10123, Italy
  • Torino, 10126, Italy
  • Vecchiazzano, 47100, Italy
  • Venezia, 30122, Italy
  • Vicenza, 36100, Italy
  • Lisboa, 1649-035, Portugal
  • Porto, 4200-072, Portugal

Showing the first 100 of 133 sites across 14 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 1998, a primary completion of Apr 2004 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 12 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2001
First posted
Mar 17, 2004
Start
Nov 1998
Primary completionActual
Apr 2004
CompletionActual
Apr 2004
Results first posted
Jun 22, 2016
Last update
Jun 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00009737
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 17, 2004
Start date
Nov 1998
Primary completion
Apr 2004
Completion
Apr 2004
Results posted
Jun 22, 2016
Last update
Jun 22, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion